Get the Stockscreener App
7.23
3.08%
-0.23
After Hours:
7.03
-0.20
-2.77%
Kamada Ltd stock is traded at $7.23, with a volume of 283.56K.
It is down -3.08% in the last 24 hours and up +0.56% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.46
Open:
$7.44
24h Volume:
283.56K
Relative Volume:
1.70
Market Cap:
$415.67M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
26.78
EPS:
0.27
Net Cash Flow:
$10.92M
1W Performance:
-7.13%
1M Performance:
+0.56%
6M Performance:
+26.40%
1Y Performance:
+17.56%
1-Day Range:
$7.07
$7.4604
1-Week Range:
$7.07
$8.02
52-Week Range:
$4.74
$9.155
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.23 | 415.67M | 154.57M | 15.07M | 10.92M | 0.27 |
|
ZTS
Zoetis Inc
|
165.31 | 74.02B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.90B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.23B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.57 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET - The Manila Times
Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung - GlobeNewswire Inc.
Alpha-1 Protease Inhibitor Deficiency Therapeutics Market - openPR
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - Finansavisen
Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 81.5% in January - MarketBeat
Kamada (NASDAQ:KMDA) Sets New 1-Year HighHere's Why - MarketBeat
Kamada (NASDAQ:KMDA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight - The Globe and Mail
Potential Price Increase for Kamada Ltd (KMDA) After Recent Insider Activity - Knox Daily
The Potential Rise in the Price of Vivid Seats Inc (SEAT) following insiders activity - Knox Daily
Kamada Ltd’s Mixed Bag: Up 45.64% in 6 Months, Up 13.09% in 30 Days - The InvestChronicle
Red Cat Holdings Inc (RCAT) Shares Soar Above 1-Year High - The News Heater
Kamada Ltd (KMDA) Shares Rise Despite Market Challenges - The News Heater
Y.D. More Investments Ltd Reduces Stock Holdings in Kamada Ltd. (NASDAQ:KMDA) - MarketBeat
Short Interest in Kamada Ltd. (NASDAQ:KMDA) Expands By 33.3% - MarketBeat
High Growth Tech Stocks To Watch In January 2025 - Simply Wall St
Kamada to supply immune globulin products in Latin America - Pharmaceutical Business Review
Kamada secures $25 million Latin America contract - MSN
Kamada Secures $25 Million Contract for Immune Globulin Products in Latin America - TipRanks
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America - The Manila Times
Kamada Secures Major $25M Contract for Life-Saving Immunoglobulin Drugs in Latin America - StockTitan
Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in December - MarketBeat
Kamada’s (KMDA) Buy Rating Reiterated at HC Wainwright - Defense World
Market Participants Recognise Kamada Ltd.'s (TLV:KMDA) Earnings Pushing Shares 25% Higher - Simply Wall St
Kamada's (KMDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations - Yahoo Finance
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 - GlobeNewswire
KMDA stock touches 52-week high at $6.53 amid market optimism By Investing.com - Investing.com South Africa
Kamada (NASDAQ:KMDA) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Comparing Endonovo Therapeutics (OTCMKTS:ENDVD) & Kamada (NASDAQ:KMDA) - Defense World
KMDA stock touches 52-week high at $6.53 amid market optimism - Investing.com Australia
Financial Survey: Kamada (NASDAQ:KMDA) versus Endonovo Therapeutics (OTCMKTS:ENDVD) - Defense World
Exploring High Growth Tech Stocks This January 2025 - Yahoo Finance
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Exploring Undiscovered Gems with Potential This December 2024 - Simply Wall St
So who replaces Eberechi Eze against Arsenal? Crystal Palace boss asked if summer signing will step in - South London News
Music Industry Moves: Avex USA Names Ryusuke Kamada CFO - Yahoo Entertainment
Kamada Ltd. Approves Board Re-Elections and Auditor Appointment - TipRanks
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.92%
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):